ChemRar, Agenus ink cancer vaccine agreement
LEXINGTON, Mass.—Agenus Inc. and NewVac LLC, a subsidiary of ChemRar High Tech Center, have announced that they have entered into a license, development and manufacturing technology transfer agreement for Agenus' Oncophage (HSPPC-96) vaccine, which is approved in Russia for the treatment of renal cancer carcinoma in patients with an intermediate risk of recurrence. NewVac gains an exclusive license to manufacture, market and sell Oncophage, and to pursue a development program of the vaccine in combination with its own co-adjuvant technology in the Russian Federation and CIS countries. Agenus is entitled to receive a transfer price and/or royalties on product sales of Oncophage, as well as potential milestone payments.
"This agreement brings us a step closer to making this product available to patients and driving further innovation in the cancer immunotherapy field," said Dr. Garo H. Armen, chairman and CEO of Agenus Inc.